AbCellera Biologics Inc.

NASDAQ:ABCL

Biotechnology

Healthcare
$11.02 -0.28%

-$0.02 today

Market cap
$3.60B
Beta
1.20
P/E (TTM)
-11.4
EPS (TTM)
-$0.47
52W Low $2.75High $6.79

Volume 2.58M

Average 6.37M

ABCL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

AbCellera Biologics Inc.NASDAQ: ABCL

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development dips below year-ago levels

Q3 FY2026 research & development of $43.54M fell 20.9% year over year, behind the +1.9% change in trailing-twelve-month research & development. Sequentially, it fell 5.3% from the prior quarter. Over 3 fiscal years it compounded at +20.1% a year.

Context

  • Research & development amounted to 248.7% of revenue in FY2025, down 331.4 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -20.9% toward the trailing-twelve-month pace of +1.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$43.54M-5.3% QoQ
Last fiscal yearDec 2025
$186.83M+11.7% YoY
LTMSep 2026
$186.28M+1.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.9%——
1 year+11.7%——
3-year CAGR+20.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
186.83M USD
Year-over-year change
+11.7%
4-year CAGR
+31.7%

Research & Development vs competitors

How ABCL compares with its peers on the latest reported figures

  • ABCL's LTM Sep 2026 research & development of $186.28M is the 3rd highest of the 4 companies compared; the peer median is $222.77M.
  • Its year-over-year change of +1.9% is the 3rd highest of 4, against a peer median of +24.0%.
  • Research & development amounts to 274.5% of revenue for ABCL, versus a peer median of 704.5%.
ABCL Competitors Peer median
Research & Development for ABCL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GENBGenerate Biomedicines, Inc.FY2025$224.7M +28.2%—704.5%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$222.77M -37.9%-38.6%157.6%
ABCLAbCellera Biologics Inc.LTM Sep 2026$186.28M +1.9%+20.1%274.5%
ABSIAbsci CorporationLTM Mar 2026$84.33M +24.0%+11.4%4593.1%
Peer median (excluding ABCL) $222.77M+24.0%-13.6%704.5%

Competitors are the stored peer set for ABCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue375.2M485.42M38.03M28.83M75.13M
Cost of Revenue45.52M66.44M0028.82M
Gross Profit329.69M418.99M38.03M28.83M46.31M
Gross Margin87.9%86.3%100.0%100.0%61.6%
Research & Development62.06M107.88M175.66M167.26M186.83M
Selling, General & Admin48.76M66.76M75.18M85.49M76.58M
Operating Expenses125.27M202.48M275.23M343.6M263.41M
Depreciation & Amortization17.25M33.1M30.89M97M28.82M
EBITDA239.15M260.17M(192.16M)(204.15M)(148.77M)
EBITDA Margin63.7%53.6%-505.3%-708.0%-198.0%
Operating Income204.41M216.51M(237.21M)(314.77M)(217.1M)
Operating Margin54.5%44.6%-623.8%-1091.7%-289.0%
Interest Income3.33M16.08M42.25M38.47M28.33M
Interest Expense5.23M4.05M000
Other Income / Expenses14.74M22.59M63.18M114.37M39.51M
Income Before Tax219.15M239.1M(174.03M)(200.4M)(177.6M)
Pre-Tax Margin58.4%49.3%-457.7%-695.0%-236.4%
Income Tax Expense65.69M80.58M(27.63M)(37.54M)(31.18M)
Net Income153.46M158.52M(146.4M)(162.86M)(146.41M)
Net Margin40.9%32.7%-385.0%-564.8%-194.9%
EPS (Basic)0.560.56(0.51)(0.55)(0.49)
EPS (Diluted)0.480.50(0.51)(0.55)(0.49)
Weighted Avg Shares275.76M285.06M289.17M294.33M298.71M
Weighted Avg Shares (Diluted)318.29M314.83M289.17M294.33M298.71M

AbCellera Biologics Inc.

NASDAQ:ABCL

Intrinsic Alpha fair value

Locked

Current Price

$11.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.